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Preterm delivery (PTD) is a complicated perinatal adverse event. We were interested in association of G308A polymorphism in
tumor necrosis factor-α (TNF-α) gene with PTD; so we conducted a genetic epidemiology study in Anqing City, Anhui Province,
China. Case families and control families were all collected between July 1999 and June 2002. To control potential population
stratiﬁcation as we could, all eligible subjects were ethnic Han Chinese. 250 case families and 247 control families were included
in data analysis. A hybrid design which combines case-parent triads and control parents was employed, to test maternal-fetal
genotype (MFG) incompatibility. The method is based on a log-linear modeling approach. In summary, we found that when
the mother’s or child’s genotype was G/A, there was a reduced risk of PTD; however when the mother’s or child’s genotype was
genotype A/A, there was a relatively higher risk of PTD. Combined maternal-fetal genotype GA/GA showed the most reduced
risk of PTD. Comparison of the LRTs showed that the model with maternal-fetal genotype eﬀects ﬁts signiﬁcantly better than the
model with only maternal and fetal genotype main eﬀects (log-likelihood=−719.4, P = .023, signiﬁcant at 0.05 level). That means
that the combined maternal-fetal genotype incompatibility was signiﬁcantly associated with PTD. The model with maternal-fetal
genotype eﬀects can be considered a gene-gene interaction model. We claim that both maternal eﬀects and fetal eﬀects should be
considered together while investigating genetic factors of certain perinatal diseases.
1.Introduction
Pretermdelivery(PTD)isoneofthemaincausesofperinatal
and neonatal death. It has been reported that PTD is
associated with some severe complications, such as cerebral
palsy, chronic respiratory illness, and blindness [1]. Even
in some developed countries like the United States, more
than 10% of newborns are preterm, and the PTD prevalence
is still increasing [2–4]. Genetic factors may be important
determinants of PTD because women who were born
preterm are more likely to deliver preterm; approximately
20% of women who delivered preterm subsequently had
another PTD with the same partner; to change partners
reduces the risk of PTD by one third and twin studies of
pregnancy outcomes estimated the heritability of PTD as
17% to 36% [5].
Increasingclinicalandlaboratorialevidencesuggeststhat
amniochorionic-decidual infections may play an important
role in PTD, by triggering a cascade of events that result in
both spontaneous preterm labor (PTL) and preterm prema-
ture rupture of membranes (PPROMs). Researchers become
interested in proinﬂammatory cytokines like tumor necrosis
factor-α (TNF-α). TNF-α is a potent cytokine which has
a wide range of proinﬂammatory activities [6]. Production
of TNF-α gene is regulated partly at transcriptional level.
An SNP from a normal guanine (G) allele to a variant
adenine (A) allele at position 308 (G308A), which is located
in the promotor region of TNF-α, is of particular interest.2 Journal of Biomedicine and Biotechnology
Transfection studies indicated that TNF-α expression is
higherinthepresenceofthe −308Aallele,comparedwiththe
−308G allele [7]. The G308A transition of TNF-α has been
shown increasing both TNF-α concentration [8] and disease
susceptibility in human subjects [9].
Large-scale studies of the association of the G308A
polymorphism of TNF-α with PTD have been conducted
only recently. However, no strong convincing evidence
of association has been found. A systematic review has
been reported, which reviewed studies investigating the
associationoftheG308ApolymorphismofTNF-αwithPTD
[10]. Those studies were reported between 1990 and 2005.
Amongthetotalsevenstudiesinvolvedinmeta-analysis,only
two reported positive results. A meta-analysis of the pooled
dataset showed no statistically signiﬁcant association. Trying
to make progress, some researchers have tested population
stratiﬁcation as a potential confounder [11–13], and some
have considered high-dimensional gene-gene interactions
[14].
It is well known that pregnancy is a complicated course,
depending on the balance between the mother and the fetus.
Maternal-fetal incompatibility is thought to be one potential
mechanismofadversepregnancyoutcomes.Therefore,while
investigating certain perinatal diseases, it is recommended
that one takes both maternal eﬀects and fetal eﬀects into
consideration. Somewhat disappointingly, few studies have
addressed association of G308A polymorphism of TNF-α
with PTD in this way. In the current study, we used a
hybriddesignwhichcombinescase-parenttriadsandcontrol
parents in the data analysis [15], to explore the complicated
eﬀects of TNF-α G308A polymorphism on PTD. This hybrid
design can bring the strengths of family-based designs and
population-based designs together to test for maternal-fetal
genotype (MFG) incompatibility, which can be considered
a form of interaction between maternal genotypes and fetal
genotypes.
2.MaterialsandMethods
2.1. Study Site and Population. Our study was conducted in
AnqingCity,AnhuiProvince,China.Thecitystretchesabout
80 km along the north bank of Yangtze River and includes
eight counties. The total population of Anqing in 2000 was
6.8 million, with 20% of it living in urban areas. The birth
rate was 15.1 per 1,000 people and the infant mortality rate
was 3.8 per 1,000 live births.
Case families and control families were collected in
Anqing Hospital between July 1999 and June 2002. Infants
and their parents were all enrolled. Cases were deﬁned as
singleton, live, preterm infants (28 completed weeks or more
but less than 37 completed weeks of gestation, regardless of
birth weight); controls were deﬁned as singleton, live, term
infants (more than 37 completed weeks of gestation). Infants
with birth defect were excluded. We matched cases and
controls by maternal age (within 5 years) and delivery date
(within2days).Tocontrolpotentialpopulationstratiﬁcation
as we could, all enrolled subjects were ethnic Han Chinese.
Besides, we enrolled only spontaneous PTD, to reduce
heterogeneity within the case group to some extent.
2.2. Data Collection Procedures. All eligible mothers were
approached by trained examiners soon after the delivery
of their children. After informed consent (approved by
the Ethics Committee of the Peking University Health
Science Center) was obtained, a structured interview was
conducted to obtain relevant information on demographic
characteristics, cigarette smoking, alcohol consumption, as
well as medical and reproductive history. Medical records of
mothers and infants were reviewed to obtain clinical data
including prenatal care, pregnancy complications, and birth
outcomes(infant’s gender,gestationalage,andbirthweight).
2.3. Blood Sample Collection and DNA Extraction. Cord
blood samples (10mL) from infants and peripheral blood
samples (10mL) from parents were collected. The blood
samples were initially stored in a −20◦C designated refriger-
ator in the Labor and Delivery Ward of the hospital and then
transported to Peking University Health Science Center, via
cold chain. DNA was extracted in our laboratory according
to standard protocols [16].
2.4. Genotyping Methods. TNF-α is located in Chromosome
6p21.3, within the major histocompatibility gene complex
[17]. We analyzed G308A polymorphism according to a
reported method [18]. Primers used for PCR were 5 -
GGGACACACAAGCATCAAGG-3  and 5 -AATAGGTTT-
TGAGGGCCATG-3 . After an initial denaturation step for
1minuteat94 ◦C, 40 cycles of ampliﬁcation were performed
as follows: 15 s at 94◦C, 30s at 60◦C, and 15 s at 72◦C
followed by a ﬁnal extension step for 7 minutes at 72◦C. We
used the Gene-Amp PCR System 9700 (Perkin-Elmer, Foster
City, CA) for ampliﬁcation. PCR products were digested
with NcoI at 37◦C. After ethidium bromide (EB) staining,
diagnostic fragments were electrophoresed in 4% agarose gel
and then visualized by UV transillumination. Genotyping
accuracy was checked by duplicate genotyping within 10%
random samples. Direct sequencing of PCR products was
also performed to ensure genotyping results.
2.5. Statistical Methods. Our analysis employed the hybrid
design reported by Weinberg and Umbach [15]a sw e l l
as the ideas of testing maternal-fetal genotype (MFG)
incompatibility reported by Sinsheimer and her colleagues
[19]. For detailed information, please refer to the original
papers.
The MFG test is based on a log-linear approach using
only case-parent triads [20], while the hybrid design using
both case-parents triads and control parents. Three key
assumptions should be considered: Mendelian transmission
ofalleles,nopopulationstratiﬁcation,andmatingsymmetry.
Mendelian transmission of the variant allele can be tested
by Transmission Disequilibrium Test (TDT), using control-
parent triads. Because the MFG test employs only case-
parent triads, mating symmetry cannot be tested [15, 21].
If one cannot trust the mating symmetry assumption,
the appropriateness of using the MFG test is in doubt.
The hybrid design provides ways of testing both the no
populationstratiﬁcationandmatingsymmetryassumptions.Journal of Biomedicine and Biotechnology 3
Luckily, even when one encounters mating asymmetry, a
modiﬁcation of the hybrid design using 9 ordered mating-
types provides an alternative inference framework.
We ﬁrst counted case-parent triads and control-parent
triads based on six mating-types. After testing Mendelian
transmission, we used the methods of testing no population
stratiﬁcation assumption and mating symmetry assumption
proposed by the hybrid design.
Equation (1) is the standard alternative model presented
by Weinberg and Umbach:
ln[E(count | M,F,C,D)]
= ln

μj

+β1DI(C=1) +β2DI(C=2)
+α1DI(M=1) +α2DI(M=2) +γD+ln (Oﬀ).
(1)
When β1 = β2 = 0, there are no child allelic eﬀects
in the model; when α1 = α2 = 0, there are no maternal
allelic eﬀects. Both of these restrictions hold under the null
model. M,F,a n dC donate the number of copies (0, 1, or
2) of the variant allele carried by the mother, the father,
and the aﬀected child, respectively. D is an indicator variable
that equals 1 for families with an aﬀected oﬀspring and 0
for control families. μj (j = 1,...,6) are proportional to the
relative frequencies in the population for the mating-type
categories. β1, β2, α1,a n dα2 are relative risk parameters.
“Oﬀ” is the probability multiplier (1, 1/2, or 1/4) for the
particular cell (see Table1 of [15]). I(C=1) denotes a dummy
independent variable that equals 1 when C = 1a n d0
otherwise. It is similar for I(C=2),I (M=1), and I(M=2).
Augmenting (1) with an predictor (M + F)D and testing
for improvement in ﬁt enables one to test whether there
is bias due to population structure. Adding an interaction
term between I(M>F) and mating-type (I(M>F) is deﬁned
as an indicator variable which is 1 when M>F and
0 otherwise), one can test mating symmetry. Retaining
any subset of (1) enables one to compare models with
or without selected terms. We followed the ideas of the
MFG test to test maternal-fetal genotype incompatibility by
reparameterizing (1) with 6 maternal-fetal genotype relative
risk combinations where the situation that both the mother
and child have genotype G/G is considered the reference
state. The Likelihood Ratio Test (LRT) is employed in model
comparison. To ease understanding the ﬁve models we
used in the current study, we present the models below
symbolically.
Model I serves as a reference model and only includes 6
mother-father mating-type eﬀects and disease eﬀects:
ln[E(count | M,F,C,D)] = In

μj

+γD+ln(Oﬀ). (I)
M o d e lI Ih a so n l yf e t a lg e n o t y p ee ﬀects, assuming no
maternal genotype eﬀects:
ln[E(count | M,F,C,D)]
= ln

μj

+β1DI(C=1) +β2DI(C=2) +γD+ln(Oﬀ).
(II)
Model III has only maternal genotype eﬀects, assuming
no fetal genotype eﬀects:
ln[E(count | M,F,C,D)]
= ln

μj

+α1DI(M=1) +α2DI(M=2) +γD+ln(Oﬀ).
(III)
Model IV is (1).
Model V includes the combined maternal-fetal genotype
eﬀects instead of maternal genotype main eﬀects and fetal
genotype main eﬀects:
ln[(count | M,F,C,D)] =
ln

μj

+δ1DI(M=2,C=2) +δ2DI(M=2,C=1) +δ3DI(M=1,C=2)
+δ4DI(M=1,C=1) +δ5DI(M=1,C=0) +δ6DI(M=0,C=1)
+γD+ln (Oﬀ).
(V)
The hybrid design employs case-parent triads and control
parents, but not controls. So the genotypes of controls in the
later analysis are treated as missing. Under this circumstance,
the expectation-maximization (EM) algorithm is used to
estimate relative risk parameters. The calculation can be
conducted in the LEM software (log-linear and event history
analysis with missing data using the EM algorithm), which
was developed by Vermunt [22]. To aid us in the somewhat
complicated calculation of EM, Weinberg and Umbach have
provided LEM scripts in their website [15].
3. Results
A total of 520 families, including 260 control families and
260 case families, participated in our study. The partici-
pation rate was 90% among the control group and 95%
among the case group. We tested maternal ethnicity or
other sociodemographic characteristics between participants
and nonparticipants and found no signiﬁcant diﬀerences.
Four case families and ﬁve control families were excluded
because we lacked their blood samples; six case families and
eight control families were excluded because of genotyping
failures. Reproducibility of genotyping was routinely greater
than 99%. We didnot encounter any cases of Mendelian
inconsistency. The ﬁnal analysis included 250 case families
and 247 control families.
Table 1 shows some general characteristics of mothers
and children.
Table 2 shows the 6 mating-types and their correspond-
ing counts, for control group and case group, respectively. In
the test of Mendelian transmission of the variant allele, we
found no statistical evidence of non-Mendelian transmission
(χ2 = 0.42, P = .522).
Although we have genotypes of controls as well, to suit
the hybrid design, we rearranged data in Table 2 to form 24
possible cells,just as described in [15, Table1]. For simplicity
of the context, we didnot provide another table here.
IntheLRTtestingwhetherthereisbiasduetopopulation
stratiﬁcation, we could not reject the null hypothesis of no4 Journal of Biomedicine and Biotechnology
Table 1: Some general characteristics of mothers and children.
Variable Control Case Preterm Delivery
Group Group OR 95%CI P-value
Age, year
19- 74 72 1 — — —
23- 99 105 1.09 0.72–1.67 .679
27- 74 73 1.01 0.64–1.60 .953
Education
≤ elementary school 75 70 1 — — —
= middle school 133 145 1.18 0.79–1.75 .431
≥ middle school 39 35 0.95 0.54–1.66 .857
Occupation
Farmer 110 111 1 — — —
worker 51 51 0.98 0.62–1.57 .935
Housewife 86 88 1.01 0.68–1.50 .955
Parity
No 171 158 1 — — —
Yes 76 92 1.28 0.89–1.86 .187
Children gender
Male 108 121 1 — — —
Female 139 129 0.82 0.58–1.17 .282
Table 2: Triad counts in control group and case group by genotype.
Mating- Triad genotype Control Group Case Group
type# (MFC)∗ (N = 247) (N = 250)
1 222 2 0
2 212 2 3
2 211 2 6
2 122 0 1
2 121 4 0
3 201 4 1
3 021 0 0
4 112 4 4
4 111 4 1
4 110 4 5
5 101 13 3
5 100 6 0
5 011 6 1
5 010 4 1
6 000 192 224
#Mating-type:decidedbythenumberofcopiesofalleletheparentscarrying.
∗Triad genotype (MFC): copies of the variant in mother, father, and child.
0: homozygous wild type; 1: heterozygous variant type; 2: homozygous
variant type.
population stratiﬁcation at the 0.05 signiﬁcance level (χ2
= 3.13, P = .077). However in testing mating symmetry,
we detected signiﬁcant evidence of violation (χ2 = 11.93,
P = .008). Therefore, we conducted our analyses with nine
ordered parental genotype categories instead of the usual six.
That is, for mating-types 2, 3, and 5, we divided them into
two ordered mating-types each.
Table 3: LRTs for maternal and fetal genotype eﬀects and their
interaction.
Model# TNF-α G308A
Log-likelihood∗ P value∗∗
I −728.3—
II −724.8 .030†
III −723.0 .005†
IV −722.0 .013†
V −719.4 .023§
#: Model I: with mating-type only; model II: with mating-type plus fetal
genotype; model III: with mating-type plus maternal genotype; model IV:
with mating-type plus fetal genotype and maternal genotype; model V: with
mating-type plus combined maternal-fetal genotype.
∗: The log-likelihoods were estimated using the LEM software.
∗∗:L R T s ,f o raχ2 distribution with df equal to the diﬀerence in the number
of parameters being ﬁtted.
†: Compared with Model I.
§: Compared with Model IV.
Table 3 shows the LRT results for the various models
w h e r em o d e lIs e r v e sa sar e f e r e n c e .C o m p a r i n gm o d e lI It o
model I, we can test for fetal genotype eﬀects, assuming no
maternal genotype eﬀects. Comparing model III to model
I, we can test for maternal genotype eﬀects, assuming no
fetal genotype eﬀects. Comparing model IV to model I tests
for both maternal genotype eﬀects and fetal genotype eﬀects
simultaneously.FinallycomparingmodelVtomodelIVtests
for maternal-fetal genotype incompatibility and is a test of
gene-gene interaction.
Table 4 shows the estimated relative risks of PTD,
given maternal and fetal TNF-α G308A polymorphism.
In summary, all the estimated relative risks of maternal
genotype main eﬀects and fetal genotype main eﬀects wereJournal of Biomedicine and Biotechnology 5
Table 4: Associations of maternal and fetal TNF-α gene G308A
genotypes with preterm delivery.
TNF-α G308A Child Mother
Genotype∗ RR 95%CI RR 95%CI
GG† 1.0 — 1.0 —
GA 0.58 0.23–1.42 0.46 0.20–1.04
AA 0.93 0.28–3.04 1.23 0.34–4.46
∗: GG: homozygous wild type; GA: heterozygous variant type; AA:
homozygous variant type.
†: Reference category.
Table 5: Association of combined maternal-fetal TNF-α G308A
genotypes with preterm delivery.
Genotypes∗ Preterm delivery
Child Mother RR 95%CI
GG GG† 1.00
GG GA 0.36 0.14–0.96§
GA GG 0.25 0.03–1.95
GA GA 0.20 0.07–0.58§
GA AA 1.12 0.41–3.10
AA GA 0.82 0.30–2.24
AA AA 0.59 0.15–2.25
∗: Use LRTs, comparing the model with an interaction term for combined
maternal-fetal genotypes against the model with maternal genotype and
fetal genotype only (without interaction term).
†: Reference category.
§: Signiﬁcant.
not signiﬁcant (95%CI of RR includes 1). Nevertheless,
mothers carrying 1 copy of the variant allele A had reduced
risk, which was almost signiﬁcant.
Table 5 presents estimated relative risks of PTD, given
certain combined maternal-fetal genotypes. Combined
maternal-fetal genotypes of GA/GG (RR = 0.36, 95%CI =
0.14–0.96) and GA/GA (RR = 0.20, 95%CI = 0.07–0.58)
showed signiﬁcant reduced risk of PTD.
4. Discussion
Because most reported studies investigating association of
TNF-α G308A polymorphism with PTD didnot consider
maternal eﬀect and fetal eﬀect together, we conducted the
current study. We were interested in the combined maternal-
fetal genotype eﬀects on PTD. We used a hybrid design
that combines case-parent triads and controls parents in the
data analysis. Assumptions of Mendelian transmission of the
variant allele and no population stratiﬁcation were satisﬁed,
but mating asymmetry was detected. So we conducted
the following analysis based on models with nine ordered
parental genotype categories instead of the usual six. Despite
some loss of power, this hybrid design provides a still-valid
analytic framework for inference, especially for maternal
genetic eﬀects [15].
Some of our results were insigniﬁcant, which may result
from sparse data. Nevertheless, compared to heterozygote
of variant allele A, homozygote of variant allele A showed
relatively higher risk of PTD (see Table 4). This is in accor-
dance with some aspects of our current understanding of the
underlying biological processes. The balance between pro-
and anti-inﬂammatory cytokines is critical for implantation,
placental development and pregnancy outcome. While the
T helper 1 (Th1) cytokine is associated with inﬂammation,
the T helper 2 (Th2) cytokine is associated with anti-
inﬂammation. The predominant expression of Th2 cytokine
islikelytobeimportanttoreduceaberrantinﬂammationand
allograft rejection of the fetus [23].
ChorioamnionitispresentstomostPTD[24].Itisknown
that chorioamnionitis with high-grade leukocyte inﬁltration
usually indicates intrauterine infection [25, 26], accompa-
nied by high concentrations of inﬂammatory mediators in
amnioticﬂuidlikeproinﬂammatorycytokines(suchasTNF-
α)[27,28].TheG308AtransitioninTNF-αpromotorregion
can increase gene expression [29, 30]. When inﬂammation
does happen, an elevated proinﬂammatory cytokines level
may result in changes of Th1/Th2 cytokine proﬁle at the
fetal-maternal interface, so as to break down the status of the
pregnant uterus as an immune-privileged organ and cause
diﬀerent adverse consequences [31]. Even if no infection
exists, proinﬂammatory cytokines can transform the uterus
from a quiescent to an active state. The cytokines stimulate
uterine activity via production of uterine activation proteins
(UAPs) [32]. An active status of the uterus increases the
possibility of PTD. These may account for why the G308A
transition increases the risk of PTD.
The eﬀect of G308A transition is far more complicated.
There is one result that needs to be mentioned: mothers
and children whose genotypes are heterozygous A/G lead
to reduced risk of PTD (see Table 4). Similar phenomenon
can be seen in the result of testing maternal-fetal geno-
type incompatibility (see Table 5). Combined maternal-fetal
genotype GA/GA showed the most reduced risk of PTD,
and this result was signiﬁcant. One possible explanation is
there are some cell membrane-bound molecules expressed
in tissues of the fetus (like cytotrophoblasts), such as Fas
ligand (FasL, also called CD95L) and TNF-related apoptosis-
inducing ligand (TRAIL) [33]. Proinﬂammatory cytokines
like TNF-α can upregulate their expression, enhance their
function, or downregulate counteracting elements against
them, which favor the apoptosis of inﬁltrated inﬂammatory
cells [34, 35]. Moderate extent of these processes might
beneﬁt pregnancy, which the genotype G/A might induce.
But of course, on the other side of the coin, if these
processes are too strong, an active status of the uterus ensues
and inevitably increases the possibility of PTD, which the
genotype A/A might induce.
Maternal genotype eﬀects have long been involved in
the study of perinatal diseases. In recent years, there have
been emerging hypotheses and evidence that the fetal
genome might be associated with pregnancy health, either by
themselves or by interacting with maternal genes. The failure
to recognize fetal contributions to pregnancy health may be
at least partially responsible for the inability to consistently
identify predisposing maternal genetic variants [36]. Since
1999, more than ten studies have investigated association of
the G308A polymorphism with PTD, but only three of them6 Journal of Biomedicine and Biotechnology
have involved both mothers and children in their studies.
Even for these three studies, none considered the mother
and the child together in their modeling. In our study, we
used a modiﬁed version of the hybrid design of Weinberg
and Umbach in an LRT framework to test. The model with
combined maternal-fetal genotype eﬀects is favored (log-
likelihood = −719.4, P = .023) over the model with just
maternal and fetal genotype main eﬀects. It implies that
fetal genotype eﬀects might contribute to PTD by interacting
with maternal genotype eﬀects. This kind of combined
maternal-fetal genotype eﬀects can be viewed as a special
maternal-fetal gene-gene interaction [36]. Pregnancy is a
complicated biologic course, and there is interplay between
the mother and the fetus. The mother needs to employ
immune-privileged processes to maintain a maternal-fetal
balance, while the fetus needs to survive immune rejection.
Regarding the result presented in Table 5, one may ﬁnd that
risk of PTD could not be predicted just simply by number of
copies carried by the mother and/or the child. It is far more
complicated. Combination of maternal-fetal genotypes, that
is maternal-fetal genotype incompatibility, deserves more of
our attention as a potential source of risk.
There are limitations in our study. First, although we
have enrolled a moderate sample size of triads, relative small
numbers of informative triads might inﬂuence the precise of
our results. Zero counts of cells may undermine the power
of LEM. This limitation partly resulted from low frequency
of the variant allele in our study population. Variant allele
frequency varies remarkable among diﬀerent races. Since
there are few large sample size studies which can provide
reliable information of TNF-α gene −308A allele frequency
in Han Chinese, further studies are warranted to conﬁrm
our results. Another limitation is that there was mating
asymmetry in our data. This limitation might be somehow
relevant to the ﬁrst one. Under mating asymmetry, the
standard MFG test [19] cannot be applied to our study.
However the hybrid design could be modiﬁed to include
MFG incompatibility and saved our study by providing a
still-valid analytic framework for inference. Finally, PTD
is likely to be etiologically heterogeneous. Although we
enrolled only spontaneous PTD, we couldn’t specify detailed
types of PTD due to practical reasons. This aspect should
be improved in future. Since we were interested in TNF-α
which is a proinﬂammatory cytokine, and chorioamnionitis
presents to most PTD, the inﬂuence of heterogeneity within
thecasegroupmaybemild.Nopopulationstratiﬁcationmay
also lessen this limitation.
5. Conclusion
In this study, we used a hybrid design and ideas of the
MFG test studying maternal-fetal genotype incompatibility,
to explore association of TNF-α G308A polymorphism
with PTD. For the ﬁrst time, as far as we know, we
have reported an association of combined maternal-fetal
TNF-α gene G308A genotypes with PTD. This association
was consistent and signiﬁcant. Besides, G308A transition
resulted in relatively higher risk of PTD for those who are
homozygous A/A, compared to those who are heterozygous
A/G. Combined maternal-fetal genotype GA/GA showed the
mostreducedriskofPTD.Butsincetherewerezerocountsin
our data, the results should be interpreted with caution and
our ﬁndings need be conﬁrmed by similar studies.
Understanding the interaction between maternal and
fetal genes is important when studying genetic factors of
perinatal diseases. Of special interest, the statistical methods
we used here are robust to the potential confounding that
can occur when investigating this interaction and use both
family-based data and population-based data. There are few
studies like ours, and so our study is of importance despite
the previously mentioned limitations.
Acknowledgments
This study is supported in part by a special fund for the
promotion of education, Ministry of Education, China. The
authors thank Professor Jeroen Vertumt for the support of
using the LEM software, Professor Clarice Weinberg and
Professor David Umbach for the LEM scripts for the hybrid
design used in this research, and Professor Janet Sinsheimer
and Professor Roger Marshall for their detailed advice on
revision.
References
[1] M. S. Esplin, “Preterm birth: a review of genetic factors
and future directions for genetic study,” Obstetrical and
Gynecological Survey, vol. 61, no. 12, pp. 800–806, 2006.
[ 2 ]R .L .G o l d e n b e r g ,J .D .I a m s ,B .M .M e r c e r ,e ta l . ,“ T h e
Preterm Prediction Study: toward a multiple-marker test for
spontaneous preterm birth,” American Journal of Obstetrics
and Gynecology, vol. 185, no. 3, pp. 643–651, 2001.
[3] J. A. Martin, B. E. Hamilton, P. D. Sutton, S. J. Ventura, F.
Menacker, and M. L. Munson, “Births: ﬁnal data for 2002,”
National Vital Statistics Reports, vol. 52, no. 10, pp. 1–113,
2003.
[4] J. A. Martin, B. E. Hamilton, P. D. Sutton, S. J. Ventura, F.
Menacker, and M. L. Munson, “Births: ﬁnal data for 2003,”
National VitalStatisticsReports,vol.54,no.2,pp.1–116, 2005.
[5] K.S.Crider,N.Whitehead,andR.M.Buus,“Geneticvariation
associated with preterm birth: a HuGE review,” Genetics in
Medicine, vol. 7, no. 9, pp. 593–604, 2005.
[6] F. Bazzoni and B. Beutler, “The tumor necrosis factor ligand
and receptor families,” New England Journal of Medicine, vol.
334, no. 26, pp. 1717–1725, 1996.
[7] W. Kaluza, E. Reuss, S. Grossmann, et al., “Diﬀerent tran-
scriptional activity and in vitro TNF-α production in psoriasis
patients carrying the TNF-α 238A promoter polymorphism,”
Journal of Investigative Dermatology, vol. 114, no. 6, pp. 1180–
1183, 2000.
[ 8 ]A .G .W i l s o n ,J .A .S y m o n s ,T .L .M c d o w e l l ,H .O .M c d e v i t t ,
and G. W. Duﬀ,“ E ﬀects of a polymorphism in the human
tumor necrosis factor α promoter on transcriptional activa-
tion,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 94, no. 7, pp. 3195–3199, 1997.
[ 9 ]B .M .N .B r i n k m a n ,D .Z u i j d g e e s t ,E .L .K a i j z e l ,F .C .
Breedveld, and C. L. Verweij, “Relevance of the tumor necrosis
factor alpha (TNFα) -308 promoter polymorphism in TNFαJournal of Biomedicine and Biotechnology 7
gene regulation,” Journal of Inﬂammation,v o l .4 6 ,n o .1 ,p p .
32–41, 1996.
[10] R. Menon, M. Merialdi, A. P. Betr´ an, et al., “Analysis of asso-
ciation between maternal tumor necrosis factor-α promoter
polymorphism (−308), tumor necrosis factor concentration,
and preterm birth,” American Journal of Obstetrics and Gyne-
cology, vol. 195, no. 5, pp. 1240–1248, 2006.
[11] R. Menon, D. R. Velez, P. Thorsen, et al., “Ethnic diﬀerences
in key candidate genes for spontaneous preterm birth: TNF-α
anditsreceptors,”HumanHeredity,vol.62,no.2,pp.107–118,
2006.
[12] R. Menon, D. R. Velez, N. Morgan, S. J. Lombardi, S. J. Fortu-
nato,andS.M.Williams,“Geneticregulationofamnioticﬂuid
TNF-alpha and soluble TNF receptor concentrations aﬀected
by race and preterm birth,” Human Genetics, vol. 124, no. 3,
pp. 243–253, 2008.
[ 1 3 ]S .J .F o r t u n a t o ,R .M e n o n ,D .R .V e l e z ,P .T h o r s e n ,a n dS .M .
Williams, “Racial disparity in maternal-fetal genetic epistasis
in spontaneous preterm birth,” American Journal of Obstetrics
and Gynecology, vol. 198, no. 6, pp. 666.e1–666.e10, 2008.
[14] R. Menon, D. R. Velez, H. Simhan, et al., “Multilocus interac-
tions at maternal tumor necrosis factor-α, tumor necrosis fac-
tor receptors, interleukin-6 and interleukin-6 receptor genes
predict spontaneous preterm labor in European-American
women,” American Journal of Obstetrics and Gynecology, vol.
194, no. 6, pp. 1616–1624, 2006.
[15] C. R. Weinberg and D. M. Umbach, “A hybrid design for
studying genetic inﬂuences on risk of diseases with onset early
in life,” American Journal of Human Genetics,v o l .7 7 ,n o .4 ,p p .
627–636, 2005.
[16] J. F. Sambrook and T. Maniatis, Molecular Cloning: A Labora-
toryManual,ColdSpringHarborLaboratoryPress,NewYork,
NY, USA, 1989.
[17] D. Pennica, G. E. Nedwin, and J. S. Hayﬂick, “Human tumour
necrosis factor: precursor structure, expression and homology
to lymphotoxin,” Nature, vol. 312, no. 5996, pp. 724–729,
1984.
[18] A. G. Wilson, F. S. Di Giovine, A. I.F. Blakemore, and G.
W. Duﬀ, “Single base polymorphism in the human Tumour
Necrosis Factor alpha (TNFα)g e n ed e t e c t a b l eb yN c o I
restriction of PCR product,” Human Molecular Genetics, vol.
1, no. 5, p. 353, 1992.
[ 1 9 ]J .S .S i n s h e i m e r ,C .G .S .P a l m e r ,a n dJ .A .W o o d w a r d ,
“Detecting genotype combinations that increase risk for
disease: the maternal-fetal genotype incompatibility test,”
Genetic Epidemiology, vol. 24, no. 1, pp. 1–13, 2003.
[20] C. R. Weinberg, A. J. Wilcox, and R. T. Lie, “A log-linear
approach to case-parent-triad data: assessing eﬀects of disease
genes that act either directly or through maternal eﬀects and
that may be subject to parental imprinting,” American Journal
of Human Genetics, vol. 62, no. 4, pp. 969–978, 1998.
[21] S. H. Vermeulen, M. Shi, C. R. Weinberg, and D. M. Umbach,
“A hybrid design: case-parent triads supplemented by control-
mother dyads,” Genetic Epidemiology, vol. 33, no. 2, pp. 136–
144, 2009.
[22] J. K. Vermunt, LEM: A General Program for the Analysis of
Categorical Data,D e p a r t m e n to fM e t h o d o l o g ya n dS t a t i s t i c s ,
Tilburg University, Tilburg, The Netherlands, 1997.
[23] S. Haider and M. Knoﬂer, “Human tumour necrosis fac-
tor: physiological and pathological roles in placenta and
endometrium,” Placenta, vol. 30, no. 2, pp. 111–123, 2009.
[24] J.Polettini,J.C.Perac ¸oli,J .M.G.C and eias,J .P .A ra´ ujoJ´ unior,
and M. G. Silva, “Inﬂammatory cytokine mRNA detection by
real time PCR in chorioamniotic membranes from pregnant
women with preterm premature rupture of membranes,”
European Journal of Obstetrics Gynecology and Reproductive
Biology, vol. 144, no. 1, pp. 27–31, 2009.
[25] K. J. Arntzen, A. M. Kjollesdal, J. Halgunset, L. Vatten, and R.
Austgulen, “TNF, IL-1, IL-6, IL-8 and soluble TNF receptors
in relation to chorioamnionitis and premature labor,” Journal
of Perinatal Medicine, vol. 26, no. 1, pp. 17–26, 1998.
[26] A. Shobokshi and M. Shaarawy, “Maternal serum and amni-
otic ﬂuid cytokines in patients with preterm premature rup-
ture of membranes with and without intrauterine infection,”
International Journal of Gynecology and Obstetrics, vol. 79, no.
3, pp. 209–215, 2002.
[27] E. Maymon, F. Ghezzi, S. S. Edwin, et al., “The tumor necrosis
factor α and its soluble receptor proﬁle in term and preterm
parturition,” American Journal of Obstetrics and Gynecology,
vol. 181, no. 5 I, pp. 1142–1148, 1999.
[28] M. Winkler, “Role of cytokines and other inﬂammatory
mediators,” British Journal of Obstetrics and Gynaecology, vol.
110, supplement 20, pp. 118–123, 2003.
[29] E. Louis, D. Franchimont, A. Piron, et al., “Tumour necrosis
factor (TNF) gene polymorphism inﬂuences TNF-α pro-
duction in lipopolysaccharide (LPS)-stimulated whole blood
cell culture in healthy humans,” Clinical and Experimental
Immunology, vol. 113, no. 3, pp. 401–406, 1998.
[30] J. Pu and W. Y. Zeng, “Relationship among TNF-alpha gene
promoter -308 site polymorphism, the levels of maternal
serum TNF-alpha, and the mRNA expression placental TNF-
alpha in preterm labor,” Sichuan Da Xue Xue Bao Yi Xue Ban,
vol. 40, no. 1, pp. 77–80, 2009.
[31] J. Trowsdale and A. G. Betz, “Mother’s little helpers: mecha-
nisms of maternal-fetal tolerance,” Nature Immunology, vol. 7,
no. 3, pp. 241–246, 2006.
[32] I. Christiaens, D. B. Zaragoza, L. Guilbert, S. A. Robertson,
B. F. Mitchell, and D. M. Olson, “Inﬂammatory processes
in preterm and term parturition,” Journal of Reproductive
Immunology, vol. 79, no. 1, pp. 50–57, 2008.
[ 3 3 ]J .Y .N i e d e r k o r n ,“ S e en oe v i l ,h e a rn oe v i l ,d on oe v i l :t h e
lessons of immune privilege,” Nature Immunology, vol. 7, no.
4, pp. 354–359, 2006.
[34] K. S. Spanaus, R. Schlapbach, and A. Fontana, “TNF-α
and IFN-γ render microglia sensitive to Fas ligand-induced
apoptosis by induction of Fas expression and down-regulation
of Bcl-2 and Bcl-xL,” European Journal of Immunology, vol. 28,
no. 12, pp. 4398–4408, 1998.
[35] B. D. Elzey, T. S. Griﬃt h ,J .M .H e r n d o n ,R .B a r r e i r o ,J .
Tschopp, and T. A. Ferguson, “Regulation of Fas ligand-
induced apoptosis by TNF,” Journal of Immunology, vol. 167,
no. 6, pp. 3049–3056, 2001.
[36] J. Chen, H. Zheng, and M. L. Wilson, “Likelihood ratio
tests for maternal and fetal genetic eﬀects on obstetric
complications,” Genetic Epidemiology, vol. 33, no. 6, pp. 526–
538, 2009.